These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Family-based exome-wide assessment of maternal genetic effects on susceptibility to childhood B-cell acute lymphoblastic leukemia in hispanics. Archer NP; Perez-Andreu V; Scheurer ME; Rabin KR; Peckham-Gregory EC; Plon SE; Zabriskie RC; De Alarcon PA; Fernandez KS; Najera CR; Yang JJ; Antillon-Klussmann F; Lupo PJ Cancer; 2016 Dec; 122(23):3697-3704. PubMed ID: 27529658 [TBL] [Abstract][Full Text] [Related]
25. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Egbelakin A; Ferguson MJ; MacGill EA; Lehmann AS; Topletz AR; Quinney SK; Li L; McCammack KC; Hall SD; Renbarger JL Pediatr Blood Cancer; 2011 Mar; 56(3):361-7. PubMed ID: 21225912 [TBL] [Abstract][Full Text] [Related]
26. Genes identified through genome-wide association studies of osteonecrosis in childhood acute lymphoblastic leukemia patients. Gagné V; Aubry-Morin A; Plesa M; Abaji R; Petrykey K; St-Onge P; Beaulieu P; Laverdière C; Alos N; Leclerc JM; Sallan SE; Neuberg D; Kutok JL; Silverman LB; Sinnett D; Krajinovic M Pharmacogenomics; 2019 Nov; 20(17):1189-1197. PubMed ID: 31686588 [No Abstract] [Full Text] [Related]
27. Genetic factors influencing the development of vincristine-induced neurotoxicity. Pozzi E; Fumagalli G; Chiorazzi A; Canta A; Cavaletti G Expert Opin Drug Metab Toxicol; 2021 Feb; 17(2):215-226. PubMed ID: 33283553 [No Abstract] [Full Text] [Related]
28. Model-Informed Precision Dosing to Reduce Vincristine-Induced Peripheral Neuropathy in Pediatric Patients: A Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis. Centanni M; van de Velde ME; Uittenboogaard A; Kaspers GJL; Karlsson MO; Friberg LE Clin Pharmacokinet; 2024 Feb; 63(2):197-209. PubMed ID: 38141094 [TBL] [Abstract][Full Text] [Related]
29. The effect of race on the CYP3A-mediated metabolism of vincristine in pediatric patients with acute lymphoblastic leukemia. Sims RP J Oncol Pharm Pract; 2016 Feb; 22(1):76-81. PubMed ID: 25305360 [TBL] [Abstract][Full Text] [Related]
31. Vincristine-induced neuropathy as the initial presentation of charcot-marie-tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study. Chauvenet AR; Shashi V; Selsky C; Morgan E; Kurtzberg J; Bell B; J Pediatr Hematol Oncol; 2003 Apr; 25(4):316-20. PubMed ID: 12679647 [TBL] [Abstract][Full Text] [Related]
32. Lack of association of the CEP72 rs924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population. Gutierrez-Camino A; Martin-Guerrero I; Lopez-Lopez E; Echebarria-Barona A; Zabalza I; Ruiz I; Guerra-Merino I; Garcia-Orad A Pharmacogenet Genomics; 2016 Feb; 26(2):100-2. PubMed ID: 26618658 [TBL] [Abstract][Full Text] [Related]
33. CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer. Skiles JL; Chiang C; Li CH; Martin S; Smith EL; Olbara G; Jones DR; Vik TA; Mostert S; Abbink F; Kaspers GJ; Li L; Njuguna F; Sajdyk TJ; Renbarger JL Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29115708 [TBL] [Abstract][Full Text] [Related]
34. Identification of genetic association between cardiorespiratory fitness and the trainability genes in childhood acute lymphoblastic leukemia survivors. Caru M; Petrykey K; Drouin S; Beaulieu P; St-Onge P; Lemay V; Bertout L; Laverdiere C; Andelfinger G; Krajinovic M; Sinnett D; Curnier D BMC Cancer; 2019 May; 19(1):443. PubMed ID: 31088516 [TBL] [Abstract][Full Text] [Related]